1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Jiangsu Sihuan Bioengineering Co., Ltd. Class A

Jiangsu Sihuan Bioengineering Co., Ltd. Class A

SSZSE:000518
3.44
CNY
-0.14
(-3.91%)
-0.05EPS
3.33BMarket Cap
Jiangsu Sihuan Bioengineering Co., Ltd. Class A
SZSE:000518
(Shenzhen Stock Exchange)

Recent

price

3.44

P/E

ratio

- -

div

yld

0.02%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.2
0.24
0.26
0.2
0.23
0.23
0.31
0.34
0.38
0.41
0.49
0.34
0.26
0.23
0.2
0.33
0.29
Revenue per Share
0.01
-0.01
0.01
-0.07
0.01
-0.07
- -
0.01
-0.03
0.01
0.03
-0.03
-0.05
-0.07
-0.11
-0.04
-0.04
Basic EPS, GAAP
0.2
-0.02
-0.01
-0.03
-0.09
-0.16
-0.01
-0.03
0.02
0.04
0.09
-0.01
- -
-0.01
- -
0.07
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.7
0.69
0.72
0.66
0.66
0.59
0.59
0.61
0.58
0.6
0.62
0.59
0.54
0.47
0.36
0.33
0.3
Book Value per Share
0.53
0.52
0.56
0.56
0.56
0.53
0.53
0.57
0.54
0.55
0.58
0.55
0.5
0.44
0.35
0.32
0.29
Tangible Book Value per Share
1,034
1,028
1,027
1,029
1,027
1,030
1,040
1,027
1,029
1,031
1,030
1,029
1,029
1,030
1,030
1,030
1,029
Basic Weighted Avg Shares
208
244
262
209
241
238
327
346
396
418
505
351
270
235
204
344
299
Sales/Revenue/Turnover
7.63
5.45
7.99
-8.05
16.16
2.34
6.61
3.67
-4.36
9.61
6.92
-6.61
-14.44
-21.14
-15.74
-8.76
-14.7
Operating Margin (%)
25
25
28
26
22
24
27
19
17
19
18
24
25
25
22
18
- -
Depreciation Expense
8
-6
10
-71
6
-74
4
7
-29
14
27
-35
-49
-75
-110
-37
-44
Net Income, GAAP
- -
47.75
31.38
- -
2,202.23
- -
56.07
36.73
- -
37.17
24.1
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
3.67
-2.44
3.84
-33.88
2.47
-31.3
1.37
2.11
-7.44
3.43
5.4
-9.91
-18.06
-31.97
-54.05
-10.77
-14.86
Profit Margin (%)
274
454
377
364
257
234
271
516
481
502
527
500
449
391
313
279
225
Working Capital
- -
- -
- -
2
- -
- -
- -
- -
- -
- -
35
31
28
26
21
15
16
LT Debt
880
916
830
731
722
609
611
676
643
660
685
647
593
513
399
359
331
Total Equity
- -
0.2
1.46
- -
-4
- -
-0.08
1.77
- -
2.68
4.47
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
-1.6
0.65
- -
-9.69
- -
1.41
0.74
- -
1.92
3.89
- -
- -
- -
- -
- -
- -
Return on Capital (%)
1.07
-0.84
1.38
-9.95
0.88
-11.56
0.73
1.18
-4.8
2.36
4.35
-5.58
-8.39
-14.49
-25.78
-10.5
-13.37
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
15
25
25
LT Borrowings
- -
- -
- -
LT Finance Leases
15
16
16
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,030
1,030
1,030
Market Capitalization
2,481
3,037
3,325

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
385
325
326
Cash, Cash Equivalents & STI
90
75
71
Accounts Receivable, Net
69
75
70
Inventories
219
170
169
Total Current Liabilities
106
103
100
Payables & Accruals
- -
- -
- -
ST Debt
15
25
25
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-4.7%
-11.91%
-9.93%
Free Cash Flow
-164.43%
-406.75%
-1,917.79%
Net Income, GAAP
-75.83%
-30.62%
-66.28%
Sales/Revenue/Turnover
7.34%
-2.16%
69.22%
Total Cash Common Dividend
4.32%
2.6%
-4.19%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
56
49
50
48
204
2025
44
138
- -
50
344
2026
81
30
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
-0.01
- -
-0.09
-0.11
2025
-0.02
0.01
- -
-0.02
-0.04
2026
-0.01
-0.01
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Jiangsu Sihuan Bioengineering Co., Ltd. (000518.SZ) engages primarily in the research, development, manufacture, and sale of biopharmaceutical products and landscaping services in China. The company produces core pharmaceutical offerings including delusen, an anti-tumor biotherapeutic drug for treating kidney cancer, malignant melanoma, and cancerous chest and abdominal masses; Xinde Lusheng; Xin Lisheng; Ring BO; injections; raw materials; tablets; alcohol-based products; and other bioengineering medicines; alongside landscaping operations such as greening construction, breeding and sales of flowers and seedlings, and tree leasing. Founded in 1992 and headquartered in Jiangyin, Wuxi, Jiangsu province, China, it operates mainly in the domestic market through subsidiaries like Jiangsu Chenwei Ecological Park Technology Co., Ltd., targeting healthcare providers and landscaping customers with approximately 277 employees. In recent developments, Fujian Bishui Agricultural Investment Co., Ltd. completed the acquisition of a 27.78% stake from Yu Qinfen, marking a significant ownership change; the company reported net losses in 2024 and into 2025 amid pharmaceutical market competition and issued its semi-annual and third-quarter 2025 reports reflecting revenue declines; additionally, its subsidiary Chenwei Ecological Park settled enforcement disputes and was removed from untrustworthy defendant lists.